Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
IPO Year: 2010
Exchange: NASDAQ
Website: alimerasciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2024 | Buy → Neutral | H.C. Wainwright | |
| 3/25/2024 | $10.00 | Buy | Maxim Group |
| 10/30/2023 | $8.00 | Neutral → Buy | Alliance Global Partners |
| 2/25/2022 | $12.00 → $10.00 | Buy | HC Wainwright & Co. |
| 8/16/2021 | $16.00 → $12.00 | Buy | HC Wainwright & Co. |
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expense by approximately $39 million on an annualized basis (1)ANI maintains its 2024 financial guidance for the standalone Company based on continued momentum across Purified Cortrophin® Gel (Cortrophin
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (NASDAQ:ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical pr
PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medic
PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (NASDAQ:ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. ("Alimera") (NASDAQ:ALIM). We note the Alimera press release issued today. The Company continues to work in good faith toward closing of the acquisition. Any delay is a result of discussions regarding closing conditions, which the Company expects to resolve promptly. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing hig
Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholders Approved Merger Agreement on September 4, Clearing Last Requirement for Closing Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced that it has filed a lawsuit in the Delaware Court of Chancery (the "Court") to compel ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") to fulfill its contractual obligation to close the transaction contemplated by the co
Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee") approved, on May 22, 2024 (the "Grant Date"), inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who were not p
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology (ARVO) conference, scheduled in Seattle, WA. from May 5 - 9 and Retina World Congress (RWC) scheduled in Fort Lauderdale, FL. from May 9 - 13. ARVO Key Abstracts: Tue, May 07 8:30am - 10:15am PT; Tedi Begaj, MD; Lisa Faia, MDCALM: 24-Month Safety Outcomes From a Real-Worl
SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13G/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13G/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13G/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13G/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13G/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13G/A - ALIMERA SCIENCES INC (0001267602) (Subject)
Alliance Global Partners analyst James Molloy downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Neutral.
Maxim Group analyst Naz Rahman downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Hold.
HC Wainwright & Co. analyst Yi Chen downgrades Alimera Sciences (NASDAQ:ALIM) from Buy to Neutral and maintains $6 price target.
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the “Fear” zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index surging more than 250 points during the session. However, the Nasdaq Composite recorded its worst session since April. Last week, the S&P 500 recorded a gain of 0.6%, while the Dow Jones index gained 1.45% to record its strongest weekly performance since May. On the economic data front, the Federal Reserve Bank of Dallas' general business activity index for manufacturing in Texas improved to -15.1 in June compared to -19.4 in May. Shares of NVIDIA Corporation (NASDAQ:NVDA) fe
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.80% to 39,463.48 while the NASDAQ fell 0.42% to 17,614.80. The S&P 500 also rose, gaining, 0.20% to 5,475.44. Leading and Lagging SectorsEnergy shares jumped by 2.6% on Monday. In trading on Monday, information technology shares fell by 1.1%. Top Headline The Federal Reserve Bank of Dallas’ general business activity index for manufacturing in Texas improved to -15.1 in June compared to -19.4 in May. Equities Trading UP Agrify Corporation (NASDAQ:AGFY) shares shot up 107% to $0.5229. Shares of MicroAlgo Inc. (NASD
On Monday, ANI Pharmaceuticals Inc (NASDAQ:ANIP) agreed to acquire Alimera Sciences Inc (NASDAQ:ALIM) for $5.50 per share in cash and one non-tradable contingent value right (CVR) of up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. ANI will also repay $72.5 million of Alimera debt. The transaction, which values Alimera at approximately $381 million in upfront consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024. Alimera’s two commercial products include Iluvien (fluocinolone acetonide intravitreal implant 0.19mg) is indicated for diabetic macular edem
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera") today announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction, which values Alimera at approximately $381 million in up front consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024, as further described below. Alimera is a globa
HC Wainwright & Co. analyst Yi Chen reiterates Alimera Sciences (NASDAQ:ALIM) with a Buy and maintains $6 price target.
Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.06) by 100 percent. This is a 83.1 percent increase over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $23.01 million which beat the analyst consensus estimate of $22.25 million by 3.42 percent. This is a 69.87 percent increase over sales of $13.55 million the same period last year.
Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup
ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sre
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our outstanding fourth quarter and full year 2023 net revenue of $26.3 million and $80.8 mill
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2023 financial results on March 7, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants can register for the conference by navigating to https://dp
Net Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful Integration of YUTIQ into the U.S. Segment ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "We are pleased to announce record net revenue of $23.4 million, a significant decrea
ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report third quarter financial results on October 26, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/
Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022Global End User Demand for ILUVIEN Up 13.5% vs. Second Quarter of 2022 ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2023. "This was a pivotal quarter for Alimera. We completed a transformational transaction to add YUTIQ to ou
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants are asked to pre-register for the call. Please note that registered partici
15-12G - ALIMERA SCIENCES INC (0001267602) (Filer)
EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)
EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)
S-8 POS - ALIMERA SCIENCES INC (0001267602) (Filer)
S-8 POS - ALIMERA SCIENCES INC (0001267602) (Filer)
S-8 POS - ALIMERA SCIENCES INC (0001267602) (Filer)
S-8 POS - ALIMERA SCIENCES INC (0001267602) (Filer)
S-8 POS - ALIMERA SCIENCES INC (0001267602) (Filer)
S-8 POS - ALIMERA SCIENCES INC (0001267602) (Filer)
S-8 POS - ALIMERA SCIENCES INC (0001267602) (Filer)
H.C. Wainwright downgraded Alimera Sciences from Buy to Neutral
Maxim Group initiated coverage of Alimera Sciences with a rating of Buy and set a new price target of $10.00
Alliance Global Partners upgraded Alimera Sciences from Neutral to Buy and set a new price target of $8.00
HC Wainwright & Co. reiterated coverage of Alimera Sciences with a rating of Buy and set a new price target of $10.00 from $12.00 previously
HC Wainwright & Co. reiterated coverage of Alimera Sciences with a rating of Buy and set a new price target of $12.00 from $16.00 previously
HC Wainwright & Co. reiterated coverage of Alimera Sciences with a rating of Buy and set a new price target of $16.00 from $14.00 previously
Alliance Global Partners reiterated coverage of Alimera Sciences with a rating of Buy and set a new price target of $15.00 from $12.00 previously
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately. "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr
ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer ("COO"), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. "Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we
ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhney, M.D. to its Board of Directors. Dr. Sawhney is presently the Chief Financial Officer for Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies. Dr. Sawhney will fill the position vacated by long term board member, Dr. Brian K. Halak. "Dr. Sawhney brings a richness of financial experience both from the pharma corporate and healthcare investment
ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President and Chief Financial Officer ("CFO"), effective today, January 9, 2023. "We are extremely excited to have someone of Russell's caliber join us here at Alimera," said Rick Eiswirth, President and CEO of Alimera. "His extensive tenure in multiple pharma sectors as well as his broad experience in acquisitions and licensing, cap
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri. "I am very excited that Dr. Dyer is joining our team in this newly created position as he brings the insights of a seasoned practicing retina specialist, and accomplished business owner to Alimera,